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A phase II clinical trial of high-dose immunochemother-
apy (HDIT; BEAM/antithymocyte globulin) and autologous
HCT was conducted in patients with highly active RRMS who
had failed conventional therapy to assess if sustained
remission could be induced. Eligibility required an EDSS of
3.0 (moderate disability, fully ambulatory) to 5.5 (severe
disability, ambulatory only 100 meters without aids) and >2
relapses on treatment in previous 18 months. Treatment-
failure was deﬁned as a composite endpoint of 1) mortality
2) relapse 3) new MRI lesions or 4) disability increase >0.5
EDSS points. Adverse events (AE) were recorded according to
NCI-CTCAE v3.0.
25 patients at a median age of 38 (27-53) years were
treatedwith G-CSF tomobilize the autograft; prednisonewas
given at the same time to prevent MS ﬂares. The autograft
was CD34-selected (Baxter, Isolex). One patient withdrew
after mobilization secondary to HIT/pulmonary embolus. 24
patients had HDIT/HCTaccording to protocol. Median follow-
up was 131 (52, 282) weeks. After initially stabilizing, one
patient died from progressive loss of neurological function at
32 months. No patient had delayed recovery of blood counts.
In the 1st year after HDIT, therewere 42 grade 3 and 6 grade 4
non-hematopoietic AE. Grade 4 AE included: one suicide
attempt (with 3 grade 4 AE); hyperuricemia; hypokalemia;
and elevated ALT. In the 2nd year, there were 13 grade 3 and 1
grade 4 non-hematopoietic AE. The 1-year and 2-year
probabilities of event-free survival (i.e. without treatment-
failure) were 95.8% (90% CI: 80.2%-99.2%) and 82.8% (90% CI:
65.0%-92.0%), respectively. Progression-free and relapse-free
survival at 1 year were 100% (90% CI: 100%-100%) and 95.8%
(90% CI: 80.2%-99.2%) and at 2 years were 91.7% (90% CI:
75.7%-97.3%) and 91.7% (90% CI: 75.7%-97.3%), respectively.
The probability of freedom from disease activity detected by
brainMRI was 95.8% (90% CI: 80.2%-99.2%) at both year 1 and
2. In comparison, a randomized clinical trial of placebo vs
natalizumab (Havrdova E et al, Lancet Neurology, 2009)
showed that 7% and 37% of RRMS patients were free of
disease activity (i.e. progression, relapse and MRI) at 2 years,
respectively.T2-weightedMRI scansmeasure disease burden fromMS.
T2 lesion volume was signiﬁcantly reduced by 6 months and
was sustained at 2 years. T1 lesion volumewas increased at 1
year. There was a signiﬁcant loss of brain volume at 6months
but stabilized thereafter.
By ﬂow cytometry, memory CD4 and CD8 T cells
(CD45ROþ) were not completely eliminated from the blood
after in vivo depletion from HDIT. The numbers of CD4 naïve
and memory T cells were not recovered at 1 year. CD4 and
CD8 recent thymic emigrants (CD45RAþ, CD31þ) were
increased at 1 year compared to the nadir at 1 month but did
not completely recover.
HDIT/HCT for highly active RRMS resulted in profound
immunosuppression and induced a high rate of sustained
remissions at 2 years.
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High-dose therapy (HDT) with autologous stem cell
transplantation (ASCT) has recently been shown to be safe
and effective in patients with central nervous system (CNS)
involvement by NHL. Rituximab (R) has been incorporated
into the therapy for CNS NHL, although there is limited
penetration of R across the intact blood brain barrier and into
the cerebrospinal ﬂuid (CSF). 23 patients were treated on
a phase II study using high-dose rituximab in combination
with high-dose cytarabine for autologous stem cell mobili-
zation followed by HDT with thiotepa, busulfan, and cyclo-
phosphamide (TBC), followed by ASCT. Median age was 58
(range 24-73). All patients received 2 doses of R at 1000 mg/
m2/dose on days 1 and 8 of high-dose cytarabine mobiliza-
tion chemotherapy and 2 doses on days -9 and -2 of TBC. 12
patients had primary CNS NHL (7 CR1, 5 relapsed) and 11
patients had secondary CNS involvement from systemic NHL.
All patients were in a chemosensitive partial or complete
remission before mobilization therapy. All patients tolerated
infusions of high dose R without reactions. All patients
achieved neutrophil engraftment (median 9 days, range 8-
12) and platelet engraftment (median 12 days, range 8-40).
The most common toxicities were diarrhea and mucositis.
Two patients developed signiﬁcant neurotoxicity, one who
had previously had whole brain radiation therapy and
another who was thought to develop thrombotic
Abstracts / Biol Blood Marrow Transplant 19 (2013) S129eS149S130microangiopathy in the setting of candidemia. The 100-day
transplant-related mortality rate was 0% and one patient
died 5 months after ASCT due to neurological complications
without evidence of lymphoma. At a median follow-up of
399 days (range 54-705 days), only one patient, who had
multiply relapsed cutaneous and CNS large cell lymphoma,
had relapsed disease, and only one patient has died. Three
patients had optional lumbar punctures performed 24-36
hours after the ﬁrst dose of high-dose R to determine CSF
levels of R. In those patients, R was present in the lumbar CSF
at concentrations of 343-498 ng/ml. CSF rituximab levels
were about 0.1% of simultaneously obtained serum concen-
trations. For patients with CNS involvement by NHL,
a regimen of high-dose R with high-dose cytarabine for stem
cell mobilization followed by high-dose R with TBC autolo-
gous stem cell transplantation is feasible. Concentrations of R
measured in the CSF are about 0.1% of that achieved in the
peripheral blood, demonstrating limited penetration past the
blood-brain-barrier. High-dose rituximab in combination
with TBC followed by ASCT shows encouraging clinical
activity and merits further study in patients with CNS NHL.38
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Engraftment syndrome (ES) is an increasingly recognized
complication of AHCT. The clinical features consist of peri-
engraftmentnon-infectious fever, skin rash, diarrhea, hepato-
renal dysfunction or capillary leak. In severe cases, ES is more
analogous to autologous graft-versus host disease (AGVHD).
In this study, we analyze a cohort of 584 consecutive AHCT
recipients for multiple myeloma (MM) or lymphoma at our
center between 2002 and 2010 to determine risk factors asso-
ciated with ES/AGVHD. Median follow-up was 49 months. To
our knowledge, this is the largest series to report on this topic.
The median age was 57 yrs with 355 males. The under-
lying disease was MM in 71% (n¼415); non-Hodgkin
lymphoma (NHL) in 20% (n¼116); and Hodgkin lymphoma
(HL) in 9% (n¼54).
Patients were identiﬁed with ES according to Maiolino
and Spitzer criteria. A total of 131 patients (22%) developed
ES (n¼104) or biopsy proven AGVHD (n¼27). Onset of clinical
ES/AGVHD was between 3 days prior and up to 10 days after
neutrophil engraftment; at a median of 12 days after AHCT.
Clinical features were fever (90%), skin rash (50%), diarrhea
(68%) and LFT abnormalities (23%). The majority (93%) were
treated with corticosteroids, achieving a complete response.
The median duration of steroids was 12 (2-151) days. Seven
patients required additional immunosuppressive treatment.
Six deaths were attributable to ES/AGVHD. Patients with ES
had longer hospital stays with a median admission of 15 days
in those without ES/AGVHD (7-58) and 17 days (12-157) in
those with ES/AGVHD (p<0.001).
By univariate analysis, ES/AGVHD was more associated
with MM and increasing patient age. Multivariate analyses
were performed stratiﬁed by disease type MM or lymphoma.
ES was signiﬁcantly more common after 2005 in the era of
novel anti-myeloma agents with ES/AGVHD only occurring in7.5% before 2005 and in 22.6% during and after 2005
(p0.001).
In multivariate models, NHL/HL was associated with
lower risk of developing ES/AGVHD (HR¼0.36, P ¼ .0003)
while age >60 yrs was associated with higher risk (HR ¼
1.94; P ¼ .001). Considering MM patients only, pre-AHCT
exposure to Lenalidomide (HR¼1.89; P¼ .005) or Bortezomib
(HR¼2.6;P < .0001) and age >60 yrs (HR¼ 2; P ¼ .001) were
strongly associated with ES/AGVHD. There was no difference
in TRM, relapse, PFS or OS between the two groups sug-
gesting a lack of graft-versus-myeloma effect with ES/
AGVHD.
In conclusion, these data demonstrate that the increasing
incidence of ES/AGVHD in recent years maybe associated
with novel agent induction in MM. Novel agent induction
may affect T cell subpopulations in the infused graft capable
of mediating ES/AGVHD.
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Although, MM remains the most common indication for
ASCT in the US, a controversy exists about the timing of ASCT.
Since earlyASCT (eASCT) versus delayedASCT (dASCT) results
in similar progression free survival (PFS) and overall survival
(OS), economic assessment of both strategies would help in
MM treatment paradigm. A decision tree was developed to
compare the outcomes of ASCT in newly diagnosed trans-
plant eligible MM patients after chemotherapy with lenali-
domide. The survival data was obtained from our published
data on eASCT versus dASCT in MM patients who underwent
initial therapy with dexamethasone + immunomodulatory
agents (IMiDs). The initial decision node on the decision tree
model was dichotomized based on the cutoff of 12 months
(m) for eASCT versus dASCT. The probabilities of events
during the length of follow up (60m) period which formed
our base case (BC) are: (a) eASCT cohort: IMiD for median of
6m> ASCT>median 30m to relapse (and drug free interval)
>median therapy of 24m for relapsedMM; (b) dASCTcohort:
